AMT inks contract with Progenika Biopharma for development of LPLchip Amsterdam Molecular Therapeutics and Progenika Biopharma announced today that the companies have entered right into a advancement and commercialization contract for LPLchip, a diagnostic device to rapidly diagnose patients with complete and partial lipoprotein lipase insufficiency . AMT is rolling out Glybera as a gene therapy for individuals with this disease. In June of this year AMT announced new clinical data showing a one-time administration of its lead product Glybera results in significant long-term health advantages for LPLD sufferers. Long-term follow-up data from two medical trials with comprehensive LPLD patients display that Glybera therapy results in a substantial and clinically important decrease in acute pancreatitis, the most debilitating complication of the disease.Based on the ACLU, law enforcement officials in at least 33 claims are actively spying on now, harassing, or elsewhere violating the free speech rights of citizens, and all in the name of fighting potential terrorism. This includes liberty-minded people who are outspoken against such federal government abuses and various types of unlawful intrusion. You will see an interactive, state-by-condition map of these First Amendment violations here: Relative to the provisions set forth by the Missouri Info Analysis Middle in its 2009 report, THE PRESENT DAY Militia Movement, individuals that question authority and government activities, or support choice political applicants like Rep.